Five prime therapeutics, inc. (FPRX)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Revenue:
Revenue from contracts with customers

14,874

49,868

39,508

30,691

-

-

-

-

-

Collaboration revenue

-

-

-

-

379,801

19,231

13,791

-

-

Collaboration revenue

-

-

-

-

-

-

-

9,983

64,916

Operating expenses:
Research and development

114,063

156,352

150,908

94,072

70,197

43,173

32,785

28,778

34,039

General and administrative

42,749

39,671

40,002

35,831

22,631

13,632

10,427

9,009

11,216

Total operating expenses

156,812

196,023

190,910

129,903

92,828

56,805

43,212

37,787

45,255

Loss from operations

-141,938

-146,155

-151,402

-99,212

286,973

-37,574

-29,421

-27,804

19,661

Interest income

4,740

5,792

2,978

2,467

487

210

62

88

114

Other expense, net

-

-

-

-

3

60

-

-

-

Other loss, net

-4

-84

-94

-

-

-

-

-

-

Other expense, net

-

-

-

-

-

-

487

121

-65

Loss before income tax

-137,202

-140,447

-148,518

-96,745

287,457

-37,424

-28,872

-

-

Income tax provision

0

0

1,704

-31,048

37,810

0

0

-

-

Net (loss) income

-

-

-

-

-

-

-

-

19,710

Net income attributable to participating securities

-

-

-

-

-

-

-

-

18,823

Net loss

-137,202

-140,447

-150,222

-65,697

249,647

-37,424

-28,872

-27,595

887

Basic

-

-

-

-

9.73

-1.79

-5.23

-23.05

0.77

Diluted

-

-

-

-

9.23

-1.79

-5.23

-23.05

0.72

Basic

-

-

-

-

25,661

20,865

5,523

1,197

1,152

Diluted

-

-

-

-

27,035

20,865

5,523

1,197

1,904

Basic and diluted net loss per common share

-3.92

-4.13

-5.38

-2.44

-

-

-

-

-

Weighted-average shares used to compute basic and diluted net loss per common share

34,970

33,976

27,945

26,955

-

-

-

-

-